MedTrace Logo

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

NCT04465695 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2020-07-15

No results posted yet for this study

Summary

To conduct an open-label randomized controlled trial on a short course of interferon β-1b and clofazimine combination treatment for patients hospitalized for COVID-19 infection. To assess its safety and clinical efficacy.

Conditions

Interventions

DRUG

Interferon beta-1b

Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days

DRUG

Clofazimine

Oral 100mg twice daily on day 1, then 100mg daily for 2 days

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ivan FN Hung, MD FRCP · HKU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2021-06-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04465695 on ClinicalTrials.gov